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Buccal drug delivery system: a tool for the effective delivery of pharmaceuticals 
 
Abstract-  
The Buccal drug delivery system includes drugadministration through the buccal mucosa, mainly 
composed of the lining of the cheeks. Buccal drug delivery system provides a convenient route 
of administration for both systemic and local drug actions.  
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Introduction 
Amongst the various routes of drug delivery, oral route is consideredbetter for patient.  Based on 
our understandings on different aspects of absorption and metabolism, many drugs cannot be 
delivered successfully through the oral route, because after administration the drugs are 
subjected to extensive pre- systemic clearance, which often leads to a lack of significant 
correlation between membrane permeability, absorption
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. 
Buccal drug delivery refers to the delivery of drugs within/through the buccal mucosa to affect 
local/systemic pharmacological actions. The buccal route is responsible for maintaining a 
delivery system at a particular position for an extended period of time therefore it has a great 
appeal for both local as well as systemic drug bioavailability
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. The buccal mucosa is relatively 
permeable with a rich blood supply and absorption occurring from this place is efficient, and the 
route also provides rapid drug transport to the systemic circulationand avoids degradation by 
gastro-intestinal enzymes and first pass hepatic metabolism
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. 
The delivery of drug requires some type of dosage form present in the oral cavity, which release 
drug and then diffuses from the mucosa into the blood flow and is then added to the blood 
circulation. 
Advantages of buccal drug delivery systems 
1. Bypass of the gastrointestinal tract and hepatic portal systemtherefore increasing the 
bioavailability of orally administered drugs that otherwise undergo hepatic first-pass metabolism.  
The drug is also protected from degradation due to pH and digestive enzymes of the middle 
gastrointestinal tract. 
 2. Improved patient compliance because of the elimination of associated pain with injections;  
 3. A relatively rapid onset of action can be achieved relative to the oral route, and the 
formulation can be removed if therapy is required to be discontinued asthe buccal patches are 
there. 
  4. Increased ease of drug administration  
 5. High blood supply and good blood flow rate cause rapid absorption. 
 6.  Mucosal surfaces do not have stratum corneum. Thus, the major barrier layer to transdermal 
drug delivery is not a factor in transmucosal routes of administration. 
Disadvantages of buccal drug delivery systems 
As compared to the sublingual membrane the buccal membrane has low permeability.  
1. Limited surface area is available for absorption.  
2. This route cannot administer drugs which irritate the mucosa or havea bitter or unpleasant 
taste or an obnoxious odour. 
 3. This route is unacceptable for those drugs which are unstable at pH of buccal environment. 
  4. The continuous secretion of the saliva (0.5-2 l/day) takes place whichleads to subsequent 
dilution of the drug.  Drugs with large dose are difficult to be administered.
4, 
5. Drugs which are unstable at buccal pH cannot be administered 
Buccal mucosa overview 
Oral mucosa is divided into two parts: 
A. Epithelium: The epithelium, act as  a protective layer for the tissues and is divided into: 
 (a) non-keratinized surface in the mucosal lining of the soft palate, the ventral surface of the 
tongue, the floor of the mouth, alveolar mucosa, vestibule, lips, and cheeks.  
 
Figure 1: Structure of buccal mucosa 
(b) Keratinized epithelium, found in the hard palate and non-flexible regions of the oral cavity.  
Basement membrane and connective tissue: Basement membrane is a boundary which is found 
in between the basal layer of epithelium and connective tissue. Itconsists of extracellular 
materials. The organisation which determines the mechanical stability, resistance to deformation, 
extendibility of tissue is made up of bulk of connective tissue.    
The cells of oral epithelia are surrounded by an intercellular grond substance called as  mucus. 
The oral cavity is marked by the presence of saliva produced by the salivary glands. 
Mucus is secreted by the major and minor glands as a part of saliva
5
. 
(B). Mucus 
The mucus is composed of proteins and carbohydrates. Mucus plays an important role in the 
absorption of buccal  dosage form. cell-cell adhesion takes place. It isassumed that the 
permeability of buccalmucosa is 4 to 4000 times greater than that of skin. 
Saliva. 
It is considered as an protective fluid for all tissues of the oral cavity. Saliva is composed of 
99.5% water in addition to proteins, glycoproteins and electrolytes. Continuous mineralization of 
the tooth enamel takes place. To hydrate oral mucosal dosage forms. 
MECHANISM OF BUCCAL ABSORPTION 
Buccal drug absorption takes place by passive diffusion of the non-ionized species. Passive 
diffusion is a process which is mainly governed  by a concentration gradient, through the 
intercellular spaces of the epithelium.  The buccal mucosa is considered as  a lipoidal barrier to 
the passage of drug 
Factors affecting buccal absorption: 
 The oral cavity is a complex environment for drug delivery as there are manyinterdependent and 
independent factors which reduces the absorbable concentration at the site of absorption. The 
factors are as follows: 
 1. Factors related with membrane: This mainly involves degree of keratinization, surface area 
available for absorption, mucus layer of salivary pellicle, intercellular lipids ofepithelium, 
basement membrane and lamina propria.  
2. Factors related with environment: 
i). Saliva: The thin film of saliva coats throughout 
the lining of buccal mucosa and is called salivary film. The thickness of salivary film is 0.07 to 
0.10 mm. The thickness, composition and movement of this film affected by the rate of buccal 
absorption. 
ii). Salivary glands: The minor salivary glands are located in epithelial or deep epithelial region 
of buccal mucosa. They constantly secrete mucus on surface of buccal mucosa.  
iii). Buccal tissues movement: Buccal region of oral cavity shows less activemovements. The 
mucoadhesive polymers are to be incorporated to keep dosage form at buccal region for long 
periods to withstand tissue movements during talking and if possible during eating food or 
swallowing
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Buccal patches 
A buccal patch is a non dissolving thin matrix modified- release dosage form. Buccal patch is 
mainly composed of one or more than one polymer films or layers containing the drug and/or 
other excipients. The patch may contain a mucoadhesive polymer layer which bonds to the oral 
mucosa, gingiva, or teeth for controlled release of the drug into the oral mucosa (unidirectional 
release), oral cavity (unidirectional release), or both (bidirectional release). Thepatch is then 
removed from the mouth and disposed of after a specified time
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Types of buccal patches 
Matrix type (Bi-directional): 
The buccal patches designed in a matrix configuration including drug, adhesive, and additives 
mixed together. Bi- directional patches release drug in both the mucosa as well as mouth.  
Reservoir type (Unidirectional):  
The buccal patch designed in a reservoir system contains a cavity for the drug and additives  
separate from the adhesive. These types of buccal patches are used fordrug delivery in the buccal 
cavity for local as well as systemic effect
8
. 
Ideal characteristics 
An ideal buccal adhesive system should possess the following characteristics:   
1) The drug should be released in a controlled fashion. 
2) The patch should facilitate the rate and extent of drug absorption. 
3) It should possess good patient compliance.   
4) It should not create problem in normal functions such as talking, eating and drinking.   
5) It  should have good resistance to the flushing action of saliva.  
Composition: 
  
Figure 2: Composition 
1. Drug- active pharmaceutical ingredient (API): 
 For buccal drug delivery, it is important to increase the contact between API and mucosa to 
obtain the desired therapeutic effect. The important drug properties that affect its diffusion 
through the patch as well as the buccal mucosa are molecular weight,chemical function and 
melting point. The selection of a suitable drug for design of buccal 
drug delivery system should be based on following characteristics:  
1. The conventional single dose of the drug should be low.   
2. The drugs having biological half-life between 2-8 hours are good candidates for controlled 
drug delivery.     
3. The drug absorption should be passive when given orally.  
4. It should not produce any irritancy, allergy and discoloration or erosion of teeth. 
2. Mucoadhesive polymers: Mucoadhesives are synthetic or natural polymers which interact 
with the mucus layer covering the mucosal epithelial surface and main molecules constituting a 
major part of mucus. Polymers are also used in matrix where the drug isembedded in the 
polymer matrix, which controls the duration of release of drugs.   
2.1. Properties of ideal mucoadhesive polymer. 
 An ideal polymer for mucoadhesive drug delivery system should have the following 
characteristics:- 
1..The polymer and its products should be non-toxic and non-absorbable from the GIT.  
2. It should not be irritant to the mucus membrane.    
3. It should allow easy incorporation of the drug and offer no hindrance to its release.  
4.The polymer must not decompose on storage or during the shelf life of the dosage form.  
5. The polymer should be easily available in the market and economical.   
3. Backing membrane: Backing membrane plays a major role in the attachmentof bioadhesive 
devices to the mucus membrane.  
1.The materials used as backing membrane should be inert. 
2.It should be impermeable to the drug and penetration enhancer. 
3.The commonly used materials in backing membrane include carbopol, magnesium separate, 
HPMC, HPC, CMC, polycarbophil etc. 
4. Penetration enhancers: Substances that facilitate the penetration through buccal mucosa are 
referred as penetration enhancers. Various compounds have been investigated for their use as 
buccal penetration and absorption enhancers which can increas the flux of drugs through the 
mucosa and act by reducing the viscosity of the mucus and saliva overcomesthis barrier
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 5. Plasticizers: These are the materials which are  used to achieve softness and flexibility of thin 
films of polymer or blend of polymers. Examples of common plasticizers includes glycerol, 
propylene glycol, PEG 200, PEG 400, castor oil etc. The plasticizers helps in releasing of the 
drug substances from the polymer base as well as acting as penetration enhancers. The choice of 
the plasticizer depends upon the ability of plasticizer material to solvate the polymer and alters 
the polymer- polymer interactions. When used in correct proportion tothe polymer, these 
materials impart flexibility by relieving the molecular rigidity. 
Preparation of mucoadhesive patches 
Mucoadhesivebuccal patches can be prepared by the following methods:  
A. Solvent casting: In this method, all ingredients are firstly weighed accurately and mixed in 
pestle and mortal. Then the mixture is added  to solvent system, which contains the plasticizer. 
The solution is then transferred to petri- dish. The petri-dish is covered with inverted funnels to 
allow evaporation of the solvents. These are kept at 20-25ºC temperature for 24 to 48 hours 
depending upon the solvent system used. After evaporation of the solvent a thin layer of the 
protective backing material is laminated onto the sheet of coated release liner to form a laminate 
that is die-cut to form patches of the desired size and geometry 
B. Direct milling: In this type of patches manufacturing there is not theuse of solvents. Drug and 
excipients are mechanically mixed by direct milling  without the presence of any liquids
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Evaluation of buccal patches. 
The following tests are used to evaluate the Buccal Patches:  
1. Weight uniformity: Five different selected patches from each batches are weighed and the 
weight variation is calculated. 
2. Thickness uniformity: The thickness of each patch is measured by using digital vernier 
calipers at five different positions of the patch and the average is calculated. 
3. Folding Endurance: The folding endurance of each patch is determined by repeatedly folding 
the patch at the same place till it is broken or folded up to 300 times, which is considered 
satisfied to reveal good film properties. 
4. Surface pH: The prepared buccal patches are  swelled for 2 hrs onthe surface of an agar plate, 
prepared by dissolving 2% (w/v) agar in warm phosphate buffer at pH 6.8 under stirring and then 
poured the solution into a petri dish till gelling at 
room temperature. The surface pH is determined by placing pH paper on the surface of the 
swollen patch. The mean of three readings is recorded. 
5. Drug content uniformity: For drug content uniformity, 3 cm patch (without backing 
membrane) is separately dissolved in 100 ml of ethanol and simulated saliva solution (pH 6.2) 
mixture (20:80) for 12 h under occasional shaking
12. 
6. Swelling Index: Buccal patches are weighed individually (W1) and placed separately in petri 
dishes containing phosphate buffer pH 6.8. The patches are removed from the petri dishes and 
excess surface water is removed using filter paper
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. The patches are reweighed (W2) and 
swelling index (SI) is calculated as follows: 
                        (W2-W1)/ W1  
7. Moisture content: The buccal patches are weighed accurately andkept in dessicator 
containing anhydrous calcium chloride. After 3 days, the patches are taken out and weighed. The 
moisture content (%) is determined by calculating moisture loss (%) using the formula:    
 
 8. In-vitro drug release: rotating paddle method is involved in studying thedrug release from 
the bilayered and multilayered patches. The dissolution medium consisted of phosphate buffer 
pH 6.8. The release is performed at 37 ± 0.5°C, with a rotation speed of 50 rpm. The backing 
layer of buccal patch is attached to the glass disk with instant material. The disk is allocated to 
the bottom of the dissolution vessel. Samples (5 ml) are withdrawn at predetermined time 
intervals and replaced with fresh medium. The samples are then filtered through whattman filter 
paper and analyzed for drug content after appropriate dilution. 
Future challenges of buccal drug delivery system
14, 15, 16 
1. The buccal drug delivery system is a promising mean for systemicdelivery of orally inefficient 
drugs as well as a feasible and attractive alternative for non-invasive delivery of potent peptide 
and protein drug molecules. Mucoadhesive drug delivery systems may be useful for many 
pharmaceuticals and can be modified to adhere to any mucosal tissue, including those found in 
oral cavity, gastrointestinal tract, vagina, eye etc. 
2. The liquid formulation of insulin plays a very important role in the treatment of Diabetes. 
Various forms of doses form. Recently due to the various research done the novel drug delivery 
system is introduced via liquid aerosol formulation has been developed. In this system the 
metered dose inhaler are introduced inside the mouth in the form of fine aerosolized drops. 
3. Development of suitable delivery devices can take place, permeation enhancement 
improvement, and buccal delivery of drugs that undergo a first-passeffect, such as cardiovascular 
drugs, analgesics, and peptides. 
4. The further research on vaccines may leads to the formulation of many new buccal products. 
5. In mucoadhesive placebo buccal patches we can use any potent drugs which fulfill the criteria 
for buccal patch as drug delivery system.  
7. In-vivo studies for the prepared mucoadhesive buccal patches may be beneficial for future 
products. 
8. Stability studies can justify the feasibility of the   
mucoadhesive buccal patches.   
9. Buccal nitroglycerin can be used for acute therapy for an anginal attack aswell as for chronic 
prophylaxis. Nitroglycerine is an important treatment for heart attack symptoms.  
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